Eek, Daniel
Blowfield, Matthew
Krogh, Calvin
Chung, Helena
Eyre, Toby A.
Funding for this research was provided by:
AstraZeneca
Article History
First Online: 18 August 2020
Declarations
:
: This qualitative study was funded by AstraZeneca. Medical writing support was provided by Anja Becher, PhD, of Oxford PharmaGenesis, Oxford, UK, and was funded by AstraZeneca.
: Daniel Eek and Helena Chung are employees of AstraZeneca and hold shares in AstraZeneca. Matthew Blowfield and Calvin Krogh are employees of IQVIA, which received funds from AstraZeneca to conduct the study. Toby A. Eyre has received honoraria from Roche, Gilead, Janssen, AbbVie, and AstraZeneca, research support from Gilead, and travel support to scientific conferences from Gilead and AbbVie.
: The patient interviews were approved by the New England Institutional Review Board.
: All interviewed patients completed an informed consent form.
: Not applicable.
: Acerta Pharma, a member of the AstraZeneca Group, is committed to data transparency and will consider data sharing requests on a case-by-case basis. Any requests for de-identified patient data can be submitted to Acerta Pharma 3 months post-publication and ending 5 years following article publication with the intent-to-achieve aims of the original proposal. In addition, Acerta Pharma will provide the study protocol, statistical analysis plan, and informed consent form, as well as post results on clinicaltrials.gov, as required.
: Not applicable.